Clinical Trial Detail

NCT ID NCT03286842
Title To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors AstraZeneca
Indications

Her2-receptor negative breast cancer

Therapies

Olaparib

Age Groups: adult senior

Additional content available in CKB BOOST